DDInter624 DDInter1951
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Warfarin
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Acenocoumarol
Acenocoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is associated with {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Warfarin
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Hydrochlorothiazide
Hydrochlorothiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Warfarin (Compound)
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Acenocoumarol (Compound) and Acenocoumarol (Compound) resembles Warfarin (Compound)
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is associated with ALB (Gene) and ALB (Gene) is bound by Warfarin (Compound)
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Fluvastatin (Compound) and Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine may lead to a major life threatening interaction when taken with Warfarin
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Methotrexate (Compound) and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin